Published • loading... • Updated
BioSyent Releases Financial Results for Q2 and H1 2026
The acquisition helped lift quarterly sales 95% and EBITDA 80%, as BioSyent added its first full quarter from the Oral Health segment.
Summary by North Bay Nipissing
4 Articles
4 Articles
North Bay Nipissing+2 Reposted by 2 other sources
BioSyent Releases Financial Results for Q2 and H1 2026
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include:
·North Bay, Canada
Read Full Article
BioSyent Declares Third Quarter 2026 Dividend
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.055 per common share, payable in Canadian Dollars on…
·Cambridge, Canada
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left2Leaning Right2Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
